Newron announces US initiation of its ENIGMA-TRS 2 Phase III global study of evenamide for patients with treatment-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback